In the $75 billion global market for generic drugs Teva Pharmaceuticals (Nasdaq:TEVA) towers over the competition. The Israel-based company's 2007 revenues of $9.4 billion amounted to more than the total of top three U.S.-headquartered generic companies combined.

Teva beat first quarter expectations with a 52% increase in adjusted net earnings. The adjustment came from a one-time charge off related to its February 2008 acquisition of CoGenesys.

Meet The Competition
Rival Mylan (NYSE:MYL) has been struggling to digest its $6.7 billion acquisition of the generic business of Merck KGaA in late 2007, and rival Barr Pharmaceuticals (NYSE:BRL) saw its shares plummet 23.3% in one day on the heels of fumbled earnings guidance. (For more on the black art of sales predictions, read Great Expectations: Forecasting Sales Growth.)

The other major U.S. generics company, Watson Pharmaceutical (NYSE:WPI) has also had a decent run so far in 2008, helped by a strong first quarter. In my opinion, though, Teva is the one with the resources and the strategic positioning to thrive over the long haul, putting yet more distance between itself and its rivals.

Generic Product, Branded Strategy
Success in the generic drug market is not about expensive, leading-edge intellectual property turning into pharmaceutical blockbusters; that's the road to success in the patent-protected world of big pharma. Success for generics comes from getting lots of product through the pipeline into the world's highest growth markets as cost-efficiently as possible. This boils down to three things: volume, location and price.

Regarding volume, as of February 2008 Teva had 160 pending abbreviated new drug applications (ANDAs), the key pipeline metric for generics. That's about double its nearest competitor Sandoz, the generic division of pharmaceutical company Novartis AG (NYSE:NVS), and further still ahead of the U.S. trio of Mylan, Barr and Watson with 71, 70 and 60 ANDAs respectively. This includes first to file status for 49 pending "Paragraph IV" applications. These are challenges to patents of existing products with over $38 billion in current U.S. sales. In terms of currently marketed products, Teva also has a clear lead over the pack with 331, compared with 200 at Sandoz and 170 at Mylan.

Geographically, Teva earns a bit more than 50% of its sales in the U.S. with the remainder coming from its two non-U.S. divisions: Europe, containing the developed markets of Western Europe as well as EU accession countries such as Poland and the Czech Republic; and International, containing many of the world's fast-growing emerging markets. The company attributed much of the 31% sales growth in the International division to strong results in Russia and Latin America as well as its own home market of Israel, which accounts for 5% of the company's total pharmaceutical sales.

In the customer's eye generics are all about price, and for manufacturers, price is all about supply chain management. Supply chain management means getting it right in terms of demand forecasting and logistics planning, not just at the next point of distribution downstream or upstream, but along the entire complex distribution network.

Teva's 14 global manufacturing locations and its investment in best-in-class supply chain management processes and technologies put it in a good position to enjoy meaningful cost-based advantages. There are also economies of scale that come with being the industry's volume leader.

The Competition Speaks
Of course Teva's competitors are by no means standing idly by while the industry leader moves ahead. Pittsburgh-based Mylan's acquisition of Merck KGaA immediately expanded its global footprint to the markets where the German company had built an extensive presence, including a number of key markets in Europe as well as Asia and Australasia.

That acquisition nearly doubled Mylan's revenue base and may provide important cost benefits down the line; however the company is experiencing some hiccups along the way, particularly with Dey, its specialty producer of inhalations solutions, injections and sprays. This unit was responsible for a $385 million goodwill impairment charge in the first quarter, hurting Mylan's earnings guidance for the rest of the year. It's on the block for divesting.

Size matters in the generic drug market. Teva is a giant, but it's a smart giant. It has a strategy that capitalizes on cost-efficient volume growth in key world markets, including emerging hotspots like Latin America, Central and Southeastern Europe. Teva's global roots, extensive product arsenal and best-of-breed logistics position it to further tighten it's grip on this industry.

To learn how to find a healthy pharmaceutical investment in a market full of weak drugs, read Measuring The Medicine Makers.

Related Articles
  1. Stock Analysis

    Will J.C. Penney Come Back in 2016? (JCP)

    J.C. Penney is without a doubt turning itself around, but that doesn't guarantee the stock will respond immediately.
  2. Stock Analysis

    Allstate: How Being Boring Earns it Billions (ALL)

    A summary of what Allstate Insurance sells and whom it sells it to including recent mergers and acquisitions that have helped boost its bottom line.
  3. Options & Futures

    Cyclical Versus Non-Cyclical Stocks

    Investing during an economic downturn simply means changing your focus. Discover the benefits of defensive stocks.
  4. Investing Basics

    How to Deduct Your Stock Losses

    Held onto a stock for too long? Selling at a loss is never ideal, but it is possible to minimize the damage. Here's how.
  5. Economics

    Is Wall Street Living in Denial?

    Will remaining calm and staying long present significant risks to your investment health?
  6. Stock Analysis

    When Will Dick's Sporting Goods Bounce Back? (DKS)

    Is DKS a bargain here?
  7. Investing News

    How AT&T Evolved into a Mobile Phone Giant

    A third of Americans use an AT&T mobile phone. How did it evolve from a state-sponsored monopoly, though antitrust and a technological revolution?
  8. Stock Analysis

    Home Depot: Can its Shares Continue Climbing?

    Home Depot has outperformed the market by a wide margin in the last 12 months. Is this sustainable?
  9. Stock Analysis

    Yelp: Can it Regain its Losses in 2016? (YELP)

    Yelp investors have had reason to be happy recently. Will the good spirits last?
  10. Stock Analysis

    Is Walmart's Rally Sustainable? (WMT)

    Walmart is enjoying a short-term rally. Is it sustainable? Is Amazon still a better bet?
  1. How do dividends affect retained earnings?

    When a company issues a cash dividend to its shareholders, the retained earnings listed on the balance sheet are reduced ... Read Full Answer >>
  2. What is the difference between called-up share capital and paid-up share capital?

    The difference between called-up share capital and paid-up share capital is investors have already paid in full for paid-up ... Read Full Answer >>
  3. Why would a corporation issue convertible bonds?

    A convertible bond represents a hybrid security that has bond and equity features; this type of bond allows the conversion ... Read Full Answer >>
  4. How does additional paid in capital affect retained earnings?

    Both additional paid-in capital and retained earnings are entries under the shareholders' equity section of a company's balance ... Read Full Answer >>
  5. What types of capital are not considered share capital?

    The money a business uses to fund operations or growth is called capital, and there are a number of capital sources available. ... Read Full Answer >>
  6. What is the difference between issued share capital and subscribed share capital?

    The difference between subscribed share capital and issued share capital is the former relates to the amount of stock for ... Read Full Answer >>

You May Also Like

Trading Center